Ultragenyx Pharmaceutical to Host Q2 2025 Financial Results Conference Call on August 5, 2025.

Ultragenyx Pharmaceutical Inc. will host a conference call on August 5, 2025, to discuss Q2 2025 financial results and corporate updates. The company focuses on rare and ultra-rare genetic diseases and has a diverse portfolio of approved therapies and product candidates. Analysts will be interested in revenue growth, R&D expenditures, and pipeline progress. The webcast will be available for three months.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on rare and ultra-rare genetic diseases, has scheduled a conference call for Tuesday, August 5, 2025, at 5:00 p.m. ET. The call will cover the company's financial performance and corporate updates for the second quarter of 2025, ending June 30, 2025.

Investors can access both the live and replay versions of the webcast through the company's investor relations website. The replay will remain available for three months following the presentation [1].

Ultragenyx Pharmaceutical is committed to developing and commercializing novel products for serious rare and ultra-rare genetic diseases. The company's portfolio includes approved therapies such as Crysvita, Dojolvi, Evkeeza, and Mepsevii, which drive revenues through direct sales, profit-sharing, and royalties worldwide. The company's pipeline includes gene therapies for highly specialized conditions like Sanfilippo syndrome, Glycogen Storage Disease Type Ia, and osteogenesis imperfecta [4].

Analysts will be closely monitoring the financial results and corporate updates to gauge revenue growth, R&D expenditures, and pipeline progress. The company's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Recent clinical setbacks, such as a mid-July interim Phase 3 trial of setrusumab for osteogenesis imperfecta that didn't pass early stopping criteria and the FDA's rejection of its Sanfilippo gene therapy, UX111, in July due to chemistry, manufacturing, and controls (CMC) issues, have impacted investor sentiment [4].

For more information on Ultragenyx Pharmaceutical, please visit the company's website at www.ultragenyx.com. Contact information for investors and media is as follows:

- Investors: Joshua Higa, ir@ultragenyx.com
- Media: Jess Rowlands, media@ultragenyx.com

References:
[1] https://www.stocktitan.net/news/RARE/ultragenyx-to-host-conference-call-for-second-quarter-2025-financial-qnhiej2vanob.html
[2] https://www.marketscreener.com/news/ultragenyx-to-host-conference-call-for-second-quarter-2025-financial-results-and-corporate-update-ce7c5fdfdd81fe2d
[3] https://finance.yahoo.com/news/ultragenyx-host-conference-call-second-123000353.html
[4] https://finimize.com/content/rare-asset-snapshot